Clinicians who routinely recommend joint supplements to patients have been working with limited options for decades. Glucosamine and chondroitin, the category’s default recommendations, have generated a large volume of research, but that research has largely failed to produce consistent, reproducible outcomes. Multiple systematic reviews and meta-analyses have found little or no meaningful benefit compared to placebo, and major clinical bodies have moved away from endorsing these supplements.
The National Center for Complementary and Integrative Health notes that current evidence does not reliably support their use for joint comfort or structural benefit. Against that backdrop, the three published human trials on Cartigenix HP® with RestorCel™ from Calroy Health Sciences represent a meaningful shift in what the published literature can offer.
Glucosamine and chondroitin have been studied extensively, yet the literature lacks consistency. The American Academy of Orthopaedic Surgeons says that glucosamine and chondroitin have contributed to pain relief and been used in both the U.S. and Europe with few side effects. However, the AAOS also notes there is no evidence to support that either substance, whether taken alone or in combination, supports cartilage structure or long-term joint function. For clinicians trying to guide patients toward evidence-supported options, these conclusions considerably narrow the field.
The three trials on Cartigenix HP with RestorCel were conducted across three different study designs, spanning more than 1,700 participants combined. The first was a prospective study (Desai 2022, n=1,236) enrolling adults aged 19 to 75 who had not responded well to standard interventions. The second was an observational study (Desai 2024, n=394). The third, and most rigorous, was a randomized, double-blind, placebo-controlled clinical trial published in Pharmaceutical Research in January 2025 (Vaidya 2025, n=62).
Taken in sequence, these trials move from initial signal detection through prospective and observational confirmation to randomized controlled verification, building an evidentiary foundation that no single trial design can produce on its own.
What makes the trial data clinically significant is the specificity of the endpoints. In the Vaidya 2025 randomized controlled trial, researchers used the WOMAC Pain Scale to assess pain and function, the 6-minute walk test to evaluate practical mobility, and serum and urinary biomarkers to assess cartilage degeneration and regeneration activity at the structural level. At 90 days, participants receiving the active intervention showed an average 67% reduction in WOMAC pain scale scores*† and an average 50% improvement in walking distance via the 6-minute walk test.† Measurable cartilage regeneration biomarkers were documented at the same 90-day endpoint, an objective signal that the intervention was influencing the underlying tissue.† Across all three studies, some participants reported noticeable changes as early as 15 days.*†
Those structural biomarker findings represent the most clinically distinct aspect of this dataset. Despite decades of published research, glucosamine and chondroitin have not produced comparable evidence of structural cartilage activity, and trials on these ingredients have relied almost exclusively on participant-reported outcomes. When functional measures and tissue-level biomarkers move in the same direction within the same 90-day window, the finding extends beyond how participants described their experience.
“What stands out about the Vaidya study isn’t just the pain reduction or the walking distance. Those are meaningful patient-reported metrics. But the biomarker data is the real shift. PIIANP and PIICP increasing in a placebo-controlled setting tells us something was happening at the tissue level, not just in how participants felt. That’s the distinction practitioners have been waiting for in this category,” said Tom Bayne, DC, educator with Calroy Health Sciences.
RestorCel, the proprietary blend powering Cartigenix HP, contains 13 standardized bioactive compounds drawn from two clinically studied botanicals: serratol from Boswellia serrata (Indian frankincense) and standardized North India celery seed extract (Apium L. graveolens). The two botanicals work through complementary pathways relevant to cartilage health, and the blend is standardized via HPLC-PDA to ensure consistent bioactive ratios across batches. The studies were conducted on the finished, standardized formulation, not on individual ingredients in isolation. Results are specific to this combination and cannot be extrapolated to generic Boswellia or celery seed products.
No adverse events were reported across all three published trials, and the participant population extended to adults up to age 75, which covers a range of joint health concerns relevant to the clinical populations most specialists see regularly.
Joint health supplementation has operated for decades on the assumption that widely used ingredients represent established science. Reproduced findings across three study designs, with consistent functional outcomes and tissue-level biomarker data, set a higher bar than the category has historically cleared.
When outcomes on WOMAC, walk distance, and cartilage biomarkers move consistently across a prospective study, an observational study, and a placebo-controlled RCT, clinicians are looking at reproduced findings rather than a single encouraging signal. Reproducibility is the quality that converts promising trial data into results clinicians can discuss with patients with reasonable confidence.
FAQ
Q: What clinical measures are used to evaluate joint supplement effectiveness?
A: Researchers commonly assess pain using validated scales such as the WOMAC, physical function using the 6-minute walk test, and structural activity through cartilage biomarkers measured in serum or urine. Using multiple endpoints in the same trial produces more clinically interpretable findings than relying on a single patient-reported outcome.
Q: Why is biomarker data meaningful in a joint health study?
A: Cartilage regeneration biomarkers provide an objective indicator of tissue-level activity that complements patient-reported pain and function scores. When both types of measures move in the same direction in the same study population, the combined signal gives clinicians a more complete picture than symptom scores alone.
Q: How should clinicians evaluate a joint supplement’s clinical evidence?
A: Key considerations include study design (randomized controlled trials carry the most interpretive weight), the number of independent studies, consistency of outcomes across designs, whether the finished formulation was studied rather than isolated ingredients, and whether biomarker data are included alongside symptom scores.
Q: What does a placebo-controlled trial add to supplement research?
A: Placebo-controlled, double-blind trials account for the expectation effect, where participants often report improvements simply because they believe they are receiving an active intervention. When a supplement produces measurable improvements in both patient-reported outcomes and objective biomarkers under blinded conditions, the findings are less likely to reflect expectation alone.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
†As shown in a placebo-controlled, randomized, controlled human research study (Vaidya 2025) and an observational study (Desai 2024). A prospective study (n=1,236) similarly demonstrated significant improvements in pain scores along with quality of life measures (Desai 2022).
